CANDEL THERAPEUTICS INC (CADL) Stock Income Statement
NASDAQ:CADL - Nasdaq - US1374041093 - Common Stock - Currency: USD
| TTM (2025-3-31) | 2024 (2024-12-31) | 2023 (2023-12-31) | 2022 (2022-12-31) | 2021 (2021-12-31) | ||||
|---|---|---|---|---|---|---|---|---|
| Revenue | 0.00 | 0.00 | 0.00 | 125.00K | 125.00K | |||
| Operating Expenses | 33.60M | 33.37M | 37.99M | 34.85M | 25.85M | |||
| Research and Development | 18.21M | 18.29M | 23.09M | 20.01M | 15.18M | |||
| Selling, General, and Administrative Expenses | 14.37M | 14.06M | 13.88M | 14.06M | 10.67M | |||
| Operating Income | -33.60M | -33.37M | -37.99M | -34.72M | -25.73M | |||
| Interest Income/Expense | -50.00K | -1.00M | -514.00K | -490.00K | -53.00K | |||
| Other Income/Expense | -5.93M | -20.80M | 966.00K | 16.42M | -10.35M | |||
| Non Recurring Items | N/A | N/A | -400.00K | N/A | N/A | |||
| Income Before Taxes | -39.58M | -55.18M | -37.94M | -18.79M | -36.12M | |||
| Income Tax | N/A | 0.00 | N/A | N/A | 0.00 | |||
| Net Income | -39.58M | -55.18M | -37.94M | -18.79M | -36.12M | |||
| EBITDA | -32.62M | -32.38M | -37.03M | -33.94M | -25.49M | |||
| Per Share Data | ||||||||
| EPS Diluted Total Ops | -1.34 | -1.74 | -1.31 | -0.65 | -1.91 | |||
| Non GAAP EPS | N/A | N/A | -1.36 | -1.12 | N/A | |||
| Statistics | ||||||||
| Profit Margin | N/A | N/A | N/A | -15035.20% | -28899.20% | |||
| Operating Profit Margin | N/A | N/A | N/A | -27777.60% | -20580.80% | |||
All data in USD